15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

MLA

Hernan Valdez, et al. “15517 Eczema Area and Severity Index 90 (EASI-90) Responder Rates with Abrocitinib and Relationship with Quality of Life (QoL) and Itch in Patients with Moderate to Severe Atopic Dermatitis: Results from a Randomized Phase 3 Clinical Trial.” Journal of the American Academy of Dermatology, vol. 83, Dec. 2020, p. AB41. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........478fe8468e62ed41efeefa90e313d8c1&authtype=sso&custid=ns315887.

APA

Hernan Valdez, Linda Stein Gold, Thomas Bieber, David A. Williams, Pinaki Biswas, Svitlana Tatulych, Gil Yosipovitch, Shawn G. Kwatra, Michael C. Cameron, & Chudy I. Nduaka. (2020). 15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial. Journal of the American Academy of Dermatology, 83, AB41.

Chicago

Hernan Valdez, Linda Stein Gold, Thomas Bieber, David A. Williams, Pinaki Biswas, Svitlana Tatulych, Gil Yosipovitch, Shawn G. Kwatra, Michael C. Cameron, and Chudy I. Nduaka. 2020. “15517 Eczema Area and Severity Index 90 (EASI-90) Responder Rates with Abrocitinib and Relationship with Quality of Life (QoL) and Itch in Patients with Moderate to Severe Atopic Dermatitis: Results from a Randomized Phase 3 Clinical Trial.” Journal of the American Academy of Dermatology 83 (December): AB41. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........478fe8468e62ed41efeefa90e313d8c1&authtype=sso&custid=ns315887.